Biotech Venture Funding: Q3 Megarounds Mask Early-Stage Strain

A strong year, on paper

By headline numbers, 2026 is shaping up as a recovery year for biopharma capital. Venture funding reached $16.3 billion across 235 rounds in the first half, according to J.P. Morgan's mid-year deal reports 1. The IPO window, shut for much of the past several years, reopened. Thirteen offerings raised $5.0 billion in the first half, more than any full-year total from 2022 through 2025 1. Two consecutive quarters of $40 billion-plus M&A, along with several large licensing deals, helped pull venture and IPO activity upward 1.

The third quarter continued the trend. BioSpace's roundup of Q3's largest raises describes money that "continued to flow," topped by Chai Discovery's $400 million Series C on July 14 3. The round valued the AI drug-discovery startup at $3.8 billion. Index Ventures, Kleiner Perkins, Sequoia Capital and Dimension led it, and OpenAI also participated 3. Further down the list, AdvanCell raised $315 million and Encoded raised $275 million 3.

Where the money is actually going

The common thread in these accounts is selectivity, not broad abundance. J.P. Morgan says capital is moving "toward later-stage assets and established programs" 1. BioSpace reports that investors preferred "advanced and derisked assets" along with AI-driven drugmakers 3. Jim Polson of FTI Consulting called the AdvanCell and Encoded rounds evidence of "continued investor interest in more advanced, increasingly de-risked programs with clear paths to meaningful clinical milestones" 3.

This preference was already visible a year earlier. J.P. Morgan's Q3 2025 report recorded $5.8 billion across 86 biopharma rounds. That was down from $6.6 billion a year before and was the smallest third-quarter total since 2022 2. The same report noted that companies with Phase II pipelines kept attracting larger rounds, with median round sizes broken out by company stage 2. Put simply, the market was already paying a premium for clinical maturity before the 2026 rebound started.

The AI exception

The main exception to the derisking rule is AI. Chai's round funds AI models meant to speed up preclinical discovery 3. That work sits at the earliest and least proven end of the drug-development pipeline, the stage investors otherwise seem to be avoiding. BioSpace connects the deal to a wider influx of tech money into biopharma. Its leading example is Alphabet's Isomorphic Labs, which raised $2.1 billion in Series B funding in May, the second-largest venture round in the industry's history 3.

This amounts to two separate risk calculations. A conventional preclinical biotech with one early asset has to compete for scarce capital and justify itself against companies already producing human data. An AI platform working at the same stage can raise hundreds of millions or billions of dollars. Its backers include investors such as OpenAI and Sequoia, who appear to see it as a technology bet as much as a drug bet 3.

Reading the gap

None of these reports gives a clean figure for early-stage biotech funding in Q3 2026. Any claim that the gap is "widening" therefore has to rest on inference, not a single measured number. The direction of the evidence is fairly consistent, though. Every source describes capital clustering around later-stage, derisked or AI-native companies 123. Exits through IPOs and $40 billion-plus M&A quarters reward the companies closest to the clinic or to commercialization 1. That makes it rational for investors to wait for data before writing checks.

The aggregate figures can hide this. A handful of megarounds, such as Isomorphic's $2.1 billion or Chai's $400 million, can account for a large share of a quarter's total dollars 3. The headline sum can look healthy while the number of conventional seed and Series A deals stays thin. Medtech shows a quieter version of the same pattern. J.P. Morgan describes venture funding there as "steady but subdued," with M&A as the main exit and IPOs selective 1.

Why it matters

The likely consequence plays out over years, not quarters. Today's Phase II companies attracting large rounds were early-stage bets several years ago. If fewer new programs get funded at inception, outside the AI-platform category, the pipeline that feeds later-stage investment and big-pharma licensing could narrow later on.

Our reading is that 2026's rebound is real but concentrated. Capital has returned to biopharma, but mostly for companies that have either already lowered their clinical risk or can present themselves as AI infrastructure. Founders with promising science who fit neither category face a much tougher market than the record IPO and megaround numbers suggest.